Safety and Efficacy of Silodosin in the Treatment of Premature Ejaculation

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of the present study aims to evaluate the safety and efficacy of Silodosin in a population of patients wih Premature Ejaculation (PE). Coupled with efficient diagnosis, it is hoped that the newer agent will improve the quality of life for patients who suffer from Premature Ejaculation (PE).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
• Treatments: Silodosin

Criteria

Inclusion Criteria:

• Premature Ejaculation (PE) diagnosed by Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) criteria.

• Stable heterosexual, monogamous relationships more than 3 months.

• Age of 20 years or order.

• Written informed consent.

Exclusion Criteria:

• α1-adrenoceptor antagonists within 4 weeks.

• Erectile dysfunction (ED) defined by an Index of Erectile Function (IIEF-5) score < 21.

• History of physical or psychological disorder (patient or partner).

• Patient need to adjust dosage during the screening and treatment period, including tricyclic antidepressants, monoamine oxidase inhibitors or selective serotonin reuptake inhibitors (SSRIs).

• Antidepressant therapy, local anaesthetic spray, intracavernosal injection or psychotherapy within 4 weeks.

• History of alcohol or drug abuse.

• Pregnant partners.